Compare BIIB & NRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | NRG |
|---|---|---|
| Founded | 1978 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 27.3B |
| IPO Year | 1996 | 1997 |
| Metric | BIIB | NRG |
|---|---|---|
| Price | $196.24 | $135.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 13 |
| Target Price | ★ $206.83 | $203.00 |
| AVG Volume (30 Days) | 849.0K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | 0.52 |
| Revenue | $9,890,600,000.00 | ★ $30,713,000,000.00 |
| Revenue This Year | N/A | $14.46 |
| Revenue Next Year | N/A | $3.12 |
| P/E Ratio | ★ $91.56 | $260.33 |
| Revenue Growth | 2.22 | ★ 9.18 |
| 52 Week Low | $121.06 | $120.11 |
| 52 Week High | $205.97 | $189.96 |
| Indicator | BIIB | NRG |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 51.43 |
| Support Level | $184.00 | $120.67 |
| Resistance Level | $199.40 | $173.02 |
| Average True Range (ATR) | 6.03 | 5.18 |
| MACD | -0.10 | 1.23 |
| Stochastic Oscillator | 62.96 | 73.09 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 26 gigawatts of coal, gas, and oil power generation capacity in Texas and the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.